- Home
- GMAB vs BLDR Comparison
GMAB vs BLDR Comparison
Compare GMAB & BLDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- BLDR
- Stock Information
- Founded
- GMAB 1999
- BLDR 1998
- Country
- GMAB Denmark
- BLDR United States
- Employees
- GMAB 2638
- BLDR N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- BLDR RETAIL: Building Materials
- Sector
- GMAB Health Care
- BLDR Consumer Discretionary
- Exchange
- GMAB Nasdaq
- BLDR Nasdaq
- Market Cap
- GMAB 13.4B
- BLDR 12.4B
- IPO Year
- GMAB N/A
- BLDR 2005
- Fundamental
- Price
- GMAB $22.25
- BLDR $113.01
- Analyst Decision
- GMAB Buy
- BLDR Strong Buy
- Analyst Count
- GMAB 9
- BLDR 19
- Target Price
- GMAB $39.17
- BLDR $170.95
- AVG Volume (30 Days)
- GMAB 1.3M
- BLDR 2.1M
- Earning Date
- GMAB 05-08-2025
- BLDR 08-05-2025
- Dividend Yield
- GMAB N/A
- BLDR N/A
- EPS Growth
- GMAB 276.80
- BLDR N/A
- EPS
- GMAB 18.36
- BLDR 7.84
- Revenue
- GMAB $3,230,902,140.00
- BLDR $16,166,636,000.00
- Revenue This Year
- GMAB $747.74
- BLDR $1.80
- Revenue Next Year
- GMAB $14.81
- BLDR $2.62
- P/E Ratio
- GMAB $1.21
- BLDR $14.45
- Revenue Growth
- GMAB 25.43
- BLDR N/A
- 52 Week Low
- GMAB $17.24
- BLDR $102.60
- 52 Week High
- GMAB $28.56
- BLDR $203.14
- Technical
- Relative Strength Index (RSI)
- GMAB 64.68
- BLDR 49.72
- Support Level
- GMAB $20.88
- BLDR $102.60
- Resistance Level
- GMAB $22.15
- BLDR $114.64
- Average True Range (ATR)
- GMAB 0.39
- BLDR 3.32
- MACD
- GMAB 0.14
- BLDR 0.61
- Stochastic Oscillator
- GMAB 94.62
- BLDR 69.87
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About BLDR Builders FirstSource Inc.
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.